The development of China’s vaccine industry in the past decade: the perspective from drug regulatory science

References

• Liu C, Cheng Y, Fan X. Translational research: development of regulatory science from regulatory science to scientific regulation. Drug Eval Res. 2014;37(5):385–91. doi:10.7501/j.1674-6376.2014.05.001.
   Google Scholar
• Shao M. The establishment and practice of bestowing the thought on scientific supervision. Manage World. 2006;(11):1–5. doi:CNKI:SUN:GLSJ.0.2006-11-000.
   Google Scholar
• Gerberding JL, Haynes BF. Vaccine innovations - past and future. N Engl J Med. 2021;384(5):393–96. doi:10.1056/NEJMp2029466.
   PubMed Web of Science ®Google Scholar
• Wang J. Overview of biopharmaceuticals regulatory science development in China. Chin New Drugs J. 2018;27(21):2465–71. doi:CNKI:SUN:ZXYZ.0.2018-21-001.
   Google Scholar
• Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020;182(3):713–21. doi:10.1016/j.cell.2020.06.008.
   PubMed Web of Science ®Google Scholar
• Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77–81. doi:10.1126/science.abc1932.
   PubMed Web of Science ®Google Scholar
• Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):951–60. doi:10.1001/jama.2020.15543.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845–54. doi:10.1016/S0140-6736(20)31208-3.
   PubMed Web of Science ®Google Scholar
• Yang S, Li Y, Dai L, Wang J, He P, Li C, Fang X, Wang C, Zhao X, Huang E, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021;21(8):1107–19. doi:10.1016/S1473-3099(21)00127-4.
   PubMed Web of Science ®Google Scholar
• Zhang NN, Li XF, Deng YQ, Zhao H, Huang YJ, Yang G, Huang WJ, Gao P, Zhou C, Zhang RR, et al. A thermostable mRNA vaccine against COVID-19. Cell. 2020;182(5):1271–83. doi:10.1016/j.cell.2020.07.024.
   PubMed Web of Science ®Google Scholar
• Standing Committee of the National People’s Congress. Vaccine administration law of the People’s Republic of China (2019 issued, order No. 30 of President of the People’s Republic of China).
   Google Scholar
• Standing Committee of the National People’s Congress. Pharmaceutical administration law of the People’s Republic of China (2019 issued, order No. 31 of President of the People’s Republic of China).
   Google Scholar
• State Administration for Market Regulation. Provisions for drug registration (2020 issued, order No. 27).
   Google Scholar
• State Administration for Market Regulation. Measures for the supervision over and administration of pharmaceutical production (Order No. 27).
   Google Scholar
• State Administration for Market Regulation. Provisions for the lot release of biological products (SFDA Order No. 33).
   Google Scholar
• Xu M, Liang Z, Xu Y, Wang J. Chinese vaccine products go global: vaccine development and quality control. Expert Rev Vaccines. 2015;14(5):763–73. doi:10.1586/14760584.2015.1012503.
   PubMed Web of Science ®Google Scholar
• Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China (2020 version).
   Google Scholar
• Liang Z, Mao Q, Wang Y, Li C, Gao K, Wang J. Regulatory science accelerates the development of biotechnology drugs and vaccines by NIFDC. Emerg Microbes Infect. 2014;3(9):e67. doi:10.1038/emi.2014.66.
   PubMed Web of Science ®Google Scholar
• Li C, Xu K, Hashem A, Shao M, Liu S, Zou Y, Gao Q, Zhang Y, Yuan L, Xu M, et al. Collaborative studies on the development of national reference standards for potency determination of H7N9 influenza vaccine. Hum Vaccin. 2015;11(6):1351–56. doi:10.1080/21645515.2015.1032490.
   PubMed Web of Science ®Google Scholar
• Cao S, Dong G, Tang J, Li J, Liu J, Shi L, Li C, Wang J. Development of a vero cell DNA reference standard for residual DNA measurement in China. Hum Vaccin Immunother. 2013;9(2):413–19. doi:10.4161/hv.22699.
   PubMed Web of Science ®Google Scholar
• Reed Z, Cardosa MJ. Status of research and development of vaccines for enterovirus 71. Vaccine. 2016;34(26):2967–71. doi:10.1016/j.vaccine.2016.02.077.
   PubMed Web of Science ®Google Scholar
• Hu Y. Improving vaccine supply and regulatory system in China. Chin J Drug Eval. 2014;31(3):175–79. doi:10.3969/j.2095-3593.2014.03.012.
   Google Scholar
• Jiang Y, Wang X, Zhu W, Qu D. The current vaccination program and related safety problem in China. J Microbes Infect. 2019;14(6):375–86. doi:10.3969/j.1673-6184.2019.06.010.
   Google Scholar
• Wang W, Wang H. Status and influencing factors of vaccination with non-expanded program on Immunization vaccines in China. Chin J Vaccines Immunization. 2020;26(1):93:97. doi:1006-916X (2020) 01-0093-05.
   Google Scholar
• Mao Q, Li N, Yu X, Yao X, Li F, Lu F, Zhuang H, Liang Z, Wang J. Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Arch Virol. 2012;157(1):27–41. doi:10.1007/s00705-011-1136-3.
   Web of Science ®Google Scholar
• Yu Z, Luo H, Fan H, Su Y, Yu X. Review and future perspectives of vaccine technology and industry development in China in the 70 years after the founding of the People’s Republic of China. Chin Med. 2019;14(7):961–65. doi:10.3760/j.1673-4777.2019.07.001.
   Google Scholar
• Jiang R, Liu X, Sun X, Wang J, Huang Z, Li C, Li Z, Zhou J, Pu Y, Ying Z, et al. Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population. Vaccine. 2021 Mar 1;39(9):1463–71. doi:10.1016/j.vaccine.2021.01.027.
   PubMed Web of Science ®Google Scholar
• Pan W, Liu Y. Progress in the research of Ebola virus vaccines. Med Inf. 2020;33(1):36–38,42. doi:10.3969/j.1006-1959.2020.01.013.
   Google Scholar
• Zhang P, Meng L, Guo X, Cai L, Pan R, Fan B, Han B. Experimental study on immunogenicity and safety of influenza vaccine. Chin J PHM. 2020;36(6):900–02. doi:10.19568/j.cnki.23-1318.2020.06.044.
   Google Scholar
• Yang X. A review of combined immunization: current research situation and its promising future. Chin J Epidemiol. 2020;41(1):120–26. doi:10.3760/cma.j.0254-6450.2020.01.022.
   Google Scholar
• Wang G, Shao M. Marketing and prospects for human vaccines in China. Chin J Vaccines Immunization. 2021;27(1):116–20. doi:10.19914/j.CJVI.2021016.
   Google Scholar
• Shao M. Thinking on scientific research framework of drug regulation in China. China Food Drug Administration. 2019;17(12):4–9. doi:10.3969/j.1673-5390.2019.12.
   Google Scholar